All Industries

All Ears for Spotify: The Rise of Audiobooks and Where You Can Listen

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/_mhl8ZVreR8 The rise of audiobooks in sales and the number of listeners cannot be ignored anymore. Audiobooks offer an entertaining, engaging way to finally get around to all the books you’ve always meant to read, a new way to experience the stories you already love and a great way to discover your next favorite book. A recent Spotify survey found that 41% of audiobook listeners prefer audiobooks over physical books because of cognitive benefits like improving their memory or keeping their mind active. The demographics leading in listening were Gen Z and Millennials, with 72% of 18–34-year-olds listening to audiobooks. On November 7th a nationwide media tour was conducted with Xavier "X" Jernigan, Spotify AI DJ x Head of Cultural Partnerships, discussing the exciting news from Spotify as they announce that audiobooks are now available to Spotify Premium subscribers in the US, introducing tens of millions of new listeners to audiobooks. Adding audiobooks into Premium means that US subscribers will have access to 15 hours of monthly listening time from a catalog of more than 200,000 audiobooks - as part of their existing Premium subscription. Spotify users are now getting even more from their Premium subscription: an on-demand catalog of more than 100 million tracks and over 200,000 audiobooks, as well as more than 5 million podcasts. The Spotify Premium audiobook catalog includes many of the world’s most beloved titles as well as new releases: including over 70% of bestselling titles. This includes books from all of the Big 5 publishers and many independent publishers and authors - including beloved titles from classics like Emily Brontë’s Wuthering Heights to modern sensations like Colleen Hoover’s It Ends With Us. For more information visiT: newsroom.spotify.com/audiobooks Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 01, 2023 10:32 AM Eastern Standard Time

Video

2023 HOLIDAY TOY DRIVE BY CHELSEA FINANCIAL SERVICES AND WHERE TO TURN BENEFITS STATEN ISLAND CHILDREN

KISS PR Brand Story

Chelsea Financial Services continues its partnership with Where to Turn, a crisis relief organization, for their 2023 Annual Holiday Toy Drive in Staten Island. With two convenient drop-off locations, Chelsea Financial continues its mission of ensuring happier holidays for children in need. 2023 ANNUAL HOLIDAY TOY DRIVE “Chelsea Financial Services has been an amazing partner for past Holiday Toy Drives, so we’re partnering again this year for our annual 2023 Drive. Their office at 242 Main Street is a convenient weekday drop-off point for unwrapped toy donations, in addition to our warehouse,” stated Dennis McKeon, Founder of Where-to-Turn.org. “John Pisapia and his team have been very involved in the community for over 25 years…Besides his annual support with the Toy Drive, his firm also sponsors Where to Turn on a monthly basis, providing website services including website design, hosting, and ADA Compliance.” “Where to Turn is an amazing local non-profit organization I’ve had the privilege to assist for many years,” added Frank Cilento, a Staten Island-based Chelsea Financial Services Representative whose son Andrew Cilento recently joined his company, FJC Financial Group. “Chelsea Financial Services is an established National Broker Dealer headquartered here on Staten Island that also has a long history of charitable giving,” explained Cilento. “So I’m very happy to help these two great organizations provide merrier Christmases to our Staten Island youth.” In addition to their popular annual Toy Drive, Where to Turn provides many other local charitable services, including a huge Prop Shop with thousands of stage props for community theater or school productions, Disaster Recovery, Snow Shoveling for Seniors, Crisis Relief, and so many more services for this New York City community. 2023 HOLIDAY TOY DRIVE INFORMATION Please drop off new and unwrapped toys at Chelsea Financial Services’ National Corporate Office located at 242 Main Street, Staten Island, any time between the hours of 9am and 5pm, Monday through Friday, through December 20th. Toys can also be dropped off on Saturdays from 12pm — 2pm at Where to Turn’s warehouse on 22 Brienna Court (Staten Island. Please join Chelsea Financial Services in helping to make this holiday season brighter for so many deserving children. About Chelsea Financial Services Chelsea Financial Services is a national full-service brokerage firm. Chelsea opened its first brokerage office in Staten Island, New York in 1999. Celebrating 25 years in 2024, Chelsea financial clients receive investment, retirement, and financial planning advice from 83 Registered Representatives based in 25 States. Visit chfs.com for more information. For Registered Representatives and Financial Advisors interested in joining Chelsea Financial Services “No Minimum Production Requirements” Team, please visit joinchelsea.com for more information or to inquire. About Where to turn Founded shortly after the terrorist attacks of September 11th, 2001, Where to Turn provides crisis relief services for victims of any kind of tragedy by helping victims obtain the help they need during the recovery process. They also create and support projects that foster community participation and interaction while assisting those in need, including their ‘Free Prom Dress Distribution’ and annual ‘Senior ‘Senior’ Prom’ projects. Visit Where to Turn for more information or to donate. Media Contact for Chelsea: John Pisapia jpisapia@chfs.com (866) 898–5800 242 Main Street, Staten Island, NY 10307 Media Contact for Where to Turn: Dennis McKeon dennis.mckeon@where-to-turn.org (718) 619–2371 22 Brienna Court, Staten Island, NY 10309 SOURCE Chelsea Financial Services Related Links https://www.chfs.com https://www.where-to-turn.org Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Release ID: 824194

December 01, 2023 10:30 AM Eastern Standard Time

Image

News Release

BuyTVInternetPhone Includes AltaFiber in its Portfolio of Internet Service Providers on Offer

KISS PR Brand Story

BuyTVInternetPhone, a facilitator of consumer access to television, Internet, and phone services across America, has announced AltaFiber as a strategic addition to its umbrella of products. The two organizations signed the deal for a partnership that will allow users searching for Internet in their localities more choices in their search for high-speed connectivity. The company conducted its due diligence and found that AltaFiber's commitment to customer satisfaction aligns with its core values. They also conducted studies with various target groups to understand their needs better. This helped them select AltaFiber as the company offered numerous packages that facilitate audiences doing remote work, learning online, or trying to scale their businesses. Talking to the press, a senior manager for the company said, "We are pleased to introduce AltaFiber Internet as an integral part of the BuyTVInternetPhone family. This strategic expansion reflects our commitment to providing comprehensive solutions in the rapidly evolving internet landscape. We had been getting calls from various target demographics like business owners, education initiatives, Gen Zs and remote workers looking to access AltaFiber to meet their needs. We take pride in concluding the deal and want to assure Americans that we will always offer them the most technologically advanced options out there." The company hopes the deal will help more customers across America, especially in rural areas, use high-speed Internet to enhance their living standards. Speaking about the partnership, a representative from Altafiber Internet said, "We are pleased to have started this partnership, which demonstrates BuyTVInternetPhone's dedication to fostering mutually beneficial collaborations that ultimately benefit the end-users. Our services have been designed to prioritize performance, reliability, and customer support in mind. Our packages are highly affordable as we strongly believe that Internet is a necessity. Our flexible contracts and pricing has helped us reach out to numerous educational institutions so students can get fast Internet for their academic pursuits among other things.” Consumers, industry professionals, and entrepreneurs interested in exploring AltaFiber's offerings can visit BuyTVInternetPhone website today: https://www.buytvinternetphone.com/ About BuyTVInternetPhone BuyTVInternetPhone is a company that is committed to simplifying the process of acquiring television, Internet connection, and phone services for consumers across America. People can enter their zip codes to get information on all the best options available in their area. The company is also committed to transparency and customer satisfaction and continues to update its portfolio of brands under its umbrella after studying the diverse needs of consumers and analyzing the market. Media Contact Contact Person: David Simokaitis Company Name: Buy TV Internet Phone Phone: +1 855-349-9328 Email: Info@buytvinternetphone.com Website: https://www.buytvinternetphone.com/ Release ID: 827765

December 01, 2023 10:00 AM Eastern Standard Time

TMNG Tokens Successfully Listed on MEXC Crypto Exchange

TMNG

TMN Global proudly announces the successful listing of its native TMNG token on the MEXC crypto exchange, effective December 1st, 2023. This strategic partnership marks a significant milestone for TMN Global in the crypto space. MEXC, a renowned player in the cryptocurrency industry, consistently securing a position among the top 15 centralized exchanges, has recently ascended to an impressive top 5 ranking on CoinGecko.com. Boasting a daily trading volume average of 1 billion USD, MEXC has firmly established itself as a major influencer in the digital asset market. TMN Global expresses its gratitude for the collaboration with MEXC exchange, which was founded in 2018 and serves over 10 million users across 170+ nations. MEXC's commitment to industry standards and professionalism aligns seamlessly with TMN Global's core values. With industry-leading features, including the lowest fees, exceptional liquidity, and a state-of-the-art security system, MEXC stands out as a top-tier crypto exchange. Their high-performance trading engine, capable of processing 1.4 million transactions per second, sets new standards for efficiency and performance in the crypto trading space. Security is paramount for both TMN Global and MEXC, with servers independently hosted across multiple countries to ensure optimal data integrity and user protection. This commitment to safety mirrors TMN Global's dedication to providing a secure environment for its investors and users. The collaboration between TMN Global and MEXC signifies a historic moment in crypto history, introducing the world's first token providing users access to technology metals and rare earth metals. The official listing on MEXC, starting December 1st, 2023, opens doors to exciting opportunities, increased liquidity, and a broader reach for TMN Global's vision. Users can stay tuned for further updates as we embark on this exciting journey together! About TMN Global: Founded in 2021, EREA World AG is a Zug, Switzerland-based blockchain company managing the TMN Global platform and native TMNG payment token. Partnered with Europäische Metallhandels (EMH) AG, TMN Global combines traditional investing in technology metals, rare earth metals, and precious metals with blockchain and cryptocurrency benefits. TMNG serves as a payment token to purchase tangible assets (metals) in the TMN Global shop. About MEXC Exchange: Established in 2018, MEXC is known for high-performance and mega transaction matching technology, catering to over 10 million users in 170+ countries. MEXC aims to become the go-to platform for new traders and experienced investors, with a global presence and regulatory compliance. The exchange's high-performance trading engine, developed by banking industry experts, completes 1.4 million transactions per second, ensuring groundbreaking efficiency and enhanced performance. Website: www.tmn-global.com Address: Poststrasse 14, 6300 Zug, Switzerland Contact Details EREA WORLD AG Rebekah Jenkins marketing@tmn-global.com

December 01, 2023 10:00 AM Eastern Standard Time

Image

Diabetes Is The Most Expensive Chronic Condition In America With Healthcare Costs Continuing To Rise, Making Addressing Its Root Causes Even More Important

Benzinga

By Faith Ashmore, Benzinga A study conducted by the CDC projects a potential 700% increase in the number of people under the age of 20 diagnosed with type 2 diabetes by2060. A substantial widening of racial and ethnic disparities is also projected as America grapples with a growing healthcare crisis driven, in part, by skyrocketing diabetes treatment costs fueled by the ‘Ozempic craze’ and the urgent need for comprehensive, accessible care. Today, diabetes is the most expensive chronic condition in America, with estimates suggesting that $1 out of $4 in healthcare is spent on diabetes. The Ozempic Craze The rising popularity of GLP-1 receptor agonists (GLP-1s) is a significant development in the field of diabetes and weight management. GLP-1s, such as liraglutide (Victoza) and semaglutide (Ozempic), have gained attention for their effectiveness in improving blood sugar control, promoting weight loss and potentially reducing the risk of cardiovascular events in individuals with type 2 diabetes. Advancements like this have unquestionably transformed the landscape of diabetes management, but it has not been without its financial (among other) implications. As more individuals turn to GLP-1s for effective blood sugar control, the costs associated with its use have garnered significant attention. Patients often find themselves grappling with high out-of-pocket expenses, as insurance coverage may not fully mitigate the financial burden. The medication's price tag, while reflective of its cutting-edge technology and effectiveness, is straining healthcare budgets. Nonetheless, it's essential to acknowledge that GLP-1s are not a panacea and that there are limitations and potential dangers in relying solely on these medications to address the complex issues of diabetes and obesity. While many experience weight loss and improved blood sugar control, some may not respond as well, or they might encounter side effects that make the medication less suitable for them. The temptation to view GLP-1s as a "magic pill" that negates the need for lifestyle and other changes is a growing concern among many in the medical community. Not only are these drugs indicated to be used as an adjunct to lifestyle modification, but ensuring patients adopt sustainable dietary modifications, increase physical activity, and prioritize adequate sleep, among other factors, remains integral to the safety and efficacy of the GLP-1s themselves, and for effective diabetes management overall. Utilizing Technology To Address Behavioral Root Causes Despite advances in pharmacotherapy, there remains a pressing need to revolutionize the approach to diabetes treatment. Better Therapeutics, Inc. (NASDAQ: BTTX) was founded with a vision to create software that guides patients in addressing the behavioral and lifestyle-related root causes of diabetes and cardiometabolic diseases. To make this vision a reality the company developed a groundbreaking form of cognitive behavioral therapy (CBT) which is accessible via a patient's smartphone. The safety and efficacy of this approach were tested in multiple clinical studies, and AspyreRx became the first FDA-authorized therapy delivering CBT via software for the treatment of type 2 diabetes. Rooted in the belief that behaviors can be learned and transformed through systematic techniques and interventions, AspyreRx offers a personalized experience to support patients in making meaningful and lasting behavioral changes to enhance their diabetes management. Delivered digitally, AspyreRx helps overcome many of the traditional limitations with in-person CBT, as a patient can access the treatment at their convenience. Better Therapeutics recently shared promising findings from a subgroup analysis from their clinical trial in type 2 diabetes. The analysis looked at a subgroup of approximately 160 participants who were already using GLP-1s as part of their diabetes treatment. The results showed that when AspyreRx was added to their treatment regimen, there was a significant improvement in their clinical outcomes compared to those who did not use AspyreRx. One of the key findings was that compared to participants using a GLP-1 and receiving standard of care treatment, the participants who used both AspyreRx and GLP-1 medications experienced an average reduction in HbA1c (a marker of blood sugar control) of 0.7% within 90 days. This reduction was higher than the results seen in the overall trial population, where AspyreRx performed better than the standard of care treatment by 0.4%. These differences were statistically significant when compared to the control group. Not only did the participants using both AspyreRx and GLP-1 medications show improvements in HbA1c levels at day 90, but they also experienced greater weight loss and needed fewer medications at day 180 compared to those who were only using GLP-1 medications. These additional benefits further support the effectiveness of AspyreRx in managing type 2 diabetes. The data from this subgroup analysis are now being submitted for peer-reviewed publication, which will add to the growing body of evidence supporting the use of AspyreRx in improving outcomes for individuals with type 2 diabetes. Making Healthcare More Accessible Beyond the clinical benefits, prescription digital therapeutics like AspyreRx hold promise in addressing health disparities and enhancing access to healthcare. They have the potential to reach and positively impact diverse populations, including those most vulnerable to diabetes, thereby helping to mitigate the looming healthcare crisis and reduce the burden of this widespread chronic condition on individuals and healthcare systems. Better Therapeutics’ innovative product and its clinical data, including this latest subgroup analysis, seem to have propelled the company into the conversation about the quickly evolving treatment landscape for diabetes and other cardiometabolic diseases. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 01, 2023 09:25 AM Eastern Standard Time

Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab

Benzinga

By Rachael Green, Benzinga This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s administered through the nose. The news marks a major milestone on the path to bring the clinical-stage company’s lead drug candidate to market. MS Patients Have Few Effective Treatment Options, And SPMS Patients Have Even Fewer The incurable disease involves recurring painful flare-ups that can be so severe people lose the ability to walk or move. This happens when the immune system attacks parts of the body’s own central nervous system, damaging nerve fibers and interrupting communication between the brain and the rest of the body. The oral medications that are available are generally immune-suppressing drugs that can reduce relapse rates. But because they are typically a blanket suppressant of the immune system, they also generally come with harmful side effects and increased risk of infection. Moreover, they aren’t always effective for patients with non-active secondary progressive MS (SPMS), the more severe and difficult-to-treat form of the disease that Tiziana is developing Foralumab for. When a flare-up strikes, the current standard of care for MS generally involves either intravenous corticosteroids for reducing inflammation or blood plasma exchange – both of which need to be done in a hospital. Positive 6-Month Clinical Results Give Hope That Foralumab Could Make A Difference In Patients’ Lives Foralumab is an anti-CD3 monoclonal antibody. It binds to the CD3 receptor on the surface of T cells in the patient’s immune system. Rather than a blanket immune suppressor, this mechanism of action selectively dampens the autoimmune response — when the T cells attack the body’s own cells — without disrupting its ability to detect and fight external pathogens. This has made it a promising candidate for fighting autoimmune diseases like MS as it has the potential to prevent painful autoimmune attacks without the severe side effects and risks that come with other immune-suppressing drugs. Tiziana reports that Foralumab is the only anti-CD3 monoclonal antibody therapy currently in development that is fully human, meaning it's even less likely to trigger adverse reactions than the genetically engineered versions being developed by other pharmaceutical companies. In October, the biopharma reported that five of the six patients who received the intranasal treatment in its expanded access program showed reduced microglia activation, a key biomarker of immune response and a possible contributing factor to the damaging flare-ups MS patients experience. Positron Emission Tomography (PET) scans of the patients at three months and six months both found decreased microglia activity in the brain. That six-month clinical data also showed improvement across a number of other measures of the disease. “Notably, in this latest clinical update for patients EA 3 through EA 6, we have seen improvement in the Modified Fatigue Impact Scale scores in three out of four patients, which is significant since fatigue is a major complaint in this population,” said Principal Investigator and Professor of Neurology at Harvard Medical School, Dr. Tanuja Chitnis, M.D. “We have also seen various degrees of improvement in the Expanded Disability Status Scale, Timed 25-Foot Walk Test, pyramidal function scores and NeuroQoL Fatigue scores in a disease state that typically shows a decline in function over time.“ Building on that positive data, Tiziana is getting ready for a new phase 2a study of the intranasal treatment. “I believe that the six-month qualitative na-SPMS PET readout by Dr. Singhal is very encouraging and will enable us to rapidly advance foralumab in Phase 2a testing to address patients afflicted with this devastating disease who currently have no FDA-approved treatments available,” said Tiziana Founder Gabriele Cerrone. Patient enrollment for the new trial is expected to begin in December 2023. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 01, 2023 09:25 AM Eastern Standard Time

Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?

Benzinga

By Meg Flippin, Benzinga COVID-19 remains a serious and deadly threat. The virus is responsible for over 200,000 deaths in the U.S. since January 2022. It continues to mutate and generate new variants at a rapid rate, putting millions of people around the globe at risk. That’s particularly true during the winter months when a triple whammy of RSV, influenza and COVID-19 causes people to get sick, some ending up in the hospital or dying as a result. There are vaccines, but with new variants taking off so quickly, those shots and boosters can become ineffective. New viruses are also expected to spread in the years to come. Available approved drugs have limitations on which patient populations they benefit, with no drugs available for most of the patients. Paxlovid (Pfizer) has the limitation that it was effective only in persons over 65 with co-morbidities, and reduced the rate of hospitalization. Remdesivir (Gilead) is only available for hospitalized patients. Molnupiravir is a mutagen and is reportedly not a effective in general use. With no end in sight, demand for more effective therapies is growing. That’s where NanoViricides, Inc. (NYSEAMERICAN: NNVC) comes in. The clinical-stage drug company is developing nanomedicine drugs to fight viruses including COVID-19, RSV and shingles. Investors Taking Notice NanoViricides isn’t yet a household name, but it seems to be getting attention from the investment community. InvestorsObserver, which ranks stocks based on a combination of technical and fundamental factors, recently gave NanoViricides an 18 rating. That puts it near the top of the healthcare sector, scoring higher than 70% of its industry peers. For good reason, NanoViricides’ drug candidate NV-CoV-2 holds promise in fighting COVID-19, RSV, and other viruses. As it makes inroads in clinical trials, the company could receive an increasing amount of attention – as it stands analysts, according to InvestorsObserver, expect shares to soar more than 350% in the next 12 months. Behind the optimism is NV-CoV-2, a drug product based on the company’s nanoviricide active pharmaceutical ingredient NV-387. NV-387 blocks the reinfection cycle of viral disease. It binds to the virus and fuses with the virus surface, uprooting the glycoproteins required for the virus to bind to the human cell, rendering it incapable of infecting a cell. NanoViricides believes NV-387 is more effective than antibodies, which can only cover the virus and not bind to it. The company likens its drug ingredient to antibiotics in that the same broad-spectrum drug NV-387 can be used to treat a variety of viruses. It now claims that the Nanoviricides platform technology is poised to revolutionize the fight against viruses just as antibiotics revolutionized the fight against bacterial infections. Clinical Trials Underway Currently, NV-CoV-2 is in phase 1 human clinical trials of two oral formulations: NV-CoV-2 Oral Syrup and NV-CoV-2 Oral gummies in India. Karveer Meditech Pvt. Ltd. is the company’s licensee and collaborator and has the rights to develop and commercialize the drugs in India. Of the 36 healthy human subjects, 26 have completed the clinical trial. No adverse events or serious adverse events were reported during the phase 1 trial, which indicates both of the formulations are safe in humans and are consistent with the company’s preclinical safety/toxicology animal studies. This excellent safety observed in humans is consistent with the Company’s preclinical data. Note that all available antiviral medicines to treat COVID-19 and for RSV as well are limited by their side effects. In addition, the company has drug candidates in development against Shingles (VZV), Herpes “Cold Sores”, Genital Herpes, Influenza (including bird flu), HIV, Dengue, Ebola/Marburg and other viruses at different preclinical stages. In many of the programs, NanoViricides has already proven animal model effectiveness and preliminary safety and is ready for candidate optimization and clinical candidate selection studies. These programs combined boast a market size of $40 to $70 billion, according to NanoViricides. The RSV therapeutics market alone is $2 to $8 Billion, per market reports. The current antiviral solutions don’t go far enough to treat and stave off these viruses. NanoViricides is hoping to change that with NV-387 and with its platform technologies. With enough cash in the bank to complete clinical trials and a commitment to its platform technology, NV-387 could be on its way to becoming the antidote needed for viruses, and biotech investors are taking notice. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 01, 2023 09:25 AM Eastern Standard Time

How Distracted Driving Prevention Systems Can Improve Companies’ Bottom Lines

Benzinga

By Meg Flippin, Benzinga Distracted driving is a leading cause of injuries and traffic fatalities in the U.S., costing billions of dollars. In 2019 distracted driving resulted in 10,546 fatalities, and 1.3 million nonfatal injuries, to the tune of $98.2 billion. All told, distracted driving accounted for 29% of all crash costs in that year. It's only getting worse thanks to TikTok and texting. For businesses that operate fleets, preventing distracted drivers has become a top priority, especially in an environment where fuel prices remain high, the cost of repairs is elevated and interest rates are rising. Even one accident puts the driver off the road, making it difficult to fulfill orders and/or meet obligations. Then there’s the cost to repair the vehicles, cover medical bills, any legal fees and increased insurance premiums. Not to mention if drivers are distracted on the road causing traffic accidents and other incidents, it can hurt the brand’s reputation and morale among employees. Distracted Driving Prevention Systems Protect The Bottom Line To reduce the number of distracted driving incidents, delivery services, transportation companies and construction firms are increasingly turning to distracted driving systems. For good reason. Sure there’s an upfront cost, but the return on the investment can come quickly if it prevents an accident. It can also lower insurance premiums, enhance operational efficiency by reducing driver fatigue, stress and errors and even improve employee retention. It shows you care about the safety and well-being of your employees. Take SaverOne 2014 Ltd. (Nasdaq: SVRE), the Israeli tech startup’s distracted driving system. It prevents drivers from using distracting apps while driving. SaverOne’s technology automatically locates the mobile device in the driver’s area and prevents the driver from using messaging and other apps. If the app is disabled, an alarm will sound. SaverOne’s technology is already installed in over 4,500 cars, trucks and buses and is integrated into the fleets of more than 100 companies worldwide. What makes it particularly unique is that its technology blocks messages but still lets the driver access navigation and other work-related applications. The company gets to set what’s allowed. What’s more, there is no action required on the part of the driver. It's automatic and doesn’t require consent. Monitoring Can Also Save Companies Money Keeping drivers focused behind the wheel is one element of reducing distracting driving, another is monitoring on the company's part. Think it doesn’t matter? Think again. By keeping an eye on how the driver is performing a company can not only promote good driving habits and dissuade bad ones, but spot problems before they become a bigger issue. In the past monitoring was reactive. The company had to wait for the vehicle to return to read the tachograph, inspect the vehicle for damage or wait until the speeding ticket came in the mail. Advances in technology have changed that. Now companies can monitor drivers from the comforts of their office in real-time thanks to GPS, cameras, radars and accelerometers to capture data on the vehicle’s movements and surroundings. Smartphone apps and wearable devices that connect to the vehicle via Bluetooth or the OBD-II port are also used to collect data on the driver’s actions and reactions. There are some systems that combine all the disparate technologies into one comprehensive system. All are designed to reduce distracted driver incidents and protect the bottom line. Distractions are coming from everywhere and companies that operate fleets are paying the price. They need to keep their drivers safe and are turning to technology to meet that end. It's the reason why over 100 companies have integrated SaverOne’s system into their fleets and why its technology is installed in over 4,500 cars, trucks and buses. In a perfect world, everyone would stay safe behind the wheel. In the real world, you need prevention and monitoring and that’s where distracted driving systems come in. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 01, 2023 09:25 AM Eastern Standard Time

News Release

Yaron Perlman’s book, DevStreams, Sheds Light on a Nature-Inspired approach for scaled Software Delivery & DX

Prodigy Press Wire

Yaron Perlman, a seasoned software delivery subject matter expert, introduces a paradigm with his book, "DevStreams Scaling Software Delivery. Naturally," that transcends traditional approaches to scaling software operations, focusing on simplicity and practicality. With 30 years of experience in designing and delivering software solutions for global companies, Perlman highlights the practicality and applicability of the DevStreams paradigm through this book. This book’s inspiration comes from a point where he identified problems in businesses. He wanted to get a full picture of the pain points that needed to be addressed and fixed. These issues were like blind spots that needed to be lifted to improve functioning. Perlman noticed that organizations often have unrealized potential. People are unable to fully utilize their work environment, maximizing productivity and capacity. Perlman believes that this gap in scaling is due to current organizational structures and dynamics. The long road to change compounds the challenge. He has provided a holistic approach. It is applicable to all, from startups to global enterprises, through this book. The unique perspective that Perlman brings is influenced by his experience as a pilot. He states, “You see the natural world from above. This enables you to transcend and see things from a different point of view. I think that this is where some of this book’s inspiration comes from, and I feel, it also has a lot to do with who I am.” Perlman compares the success of nature in scaling despite its complexity, to the problem of scaling productivity and minimizing waste. He finds that nature addresses this problem through fractals and branching structures. Combining the fundamental behavior of nature and applying it to software delivery, Perlman hopes to provide a valuable resource for organizations looking to improve their operations and achieve their goals. A notable strength of the DevStreams book lies in its accessibility to individuals beyond the software delivery realm. Perlman's intentional avoidance of complex language and sentences makes the book approachable for anyone seeking inspiration for personal and professional growth. To avoid siloed knowledge, Perlman gave the book to his friends to gauge feedback from other industries. The feedback was overwhelmingly positive, demonstrating the book's potential for scaling in terms of value, volume, and velocity. The book promotes a culture of questioning, creativity, and adaptability. Perlman encourages readers to think outside the box. He emphasizes that the book does not provide a cookie-cutter solution but rather a toolkit for organizations and individuals to navigate challenges with resilience. Media Contact: Name: Yaron Perlman Email: yaron@devstreams.com Release ID: 827956

December 01, 2023 09:00 AM Eastern Standard Time

1 ... 737 738 739 740 741 ... 3895